ABS37: Add-on omalizumab improves asthma control across multiple measures of response in patients with severe persistent allergic (IgE-mediated) asthma

INTRODUCTION: Omalizumab is a novel anti-IgE therapy for patients having inadequately controlled severe persistent allergic asthma with uncontrolled symptoms despite GINA 2002 step 4 therapy (inhaled ICS + LABA∓ additional controller medication as necessary). Omalizumab reduces exacerbations in thes...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Prim Care Respir J
Egile Nagusiak: Price, D., Fox, H., Ayre, G., Blogg, M., Massanari, M., Reisner, C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2006
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6730752/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pcrj.2006.04.136
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak